Model-Based Approach to Design Bispecific Modalities in Early Discovery

Webinar Details

This webinar aired live on Tuesday, February 4, 2020 at 2PM ET / 11AM PT and was presented by Dr. Jennifer Fretland, Head of DMPK US, Sanofi.

Bi-specific antibodies are an attractive modality to modulate multiple targets in a disease indication.  Each antigen may exhibit similar or different kinetic values like half-life, internalization rates, and expression rates. Target coverage for each antigen may also differ or be similar. 

Understanding your drug targets is critical to building an appropriate drug that specifically binds to and elicits the magnitude and duration of response needed for a particular indication. Here we used a tiered model-based approach to first determine feasibility of a bi-specific antibody to appropriately cover multiple antigen pairs. Once feasibility was assessed, further modeling was performed to determine ideal affinity ranges for each target in bi-specific format at the site of action.  Sensitivity analysis was performed to understand each parameter and its impact on predicted target coverage. This approach guided teams for informed antibody design, prioritization of experiments, and triaging of challenging antigen pairs.  

View the Webinar